Siddhartha Yadav1, Rand Ladkany2, Dhiraj Yadav3, Omar Alhalabi4, Sinan Khaddam5, Daniel Isaac6, Paola Yumpo Cardenas7, Dana Zakalik8. 1. Hematology-Oncology Fellowship Program, Mayo Clinic, Rochester, MN. Electronic address: yadav.siddhartha@mayo.edu. 2. Nancy and James Grosfeld Cancer Genetics Center, Beaumont Cancer Institute, Beaumont Health, Royal Oak, MI; Department of Internal Medicine, Beaumont Health, Royal Oak, MI. 3. Department of Internal Medicine, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH. 4. Hematology-Oncology Fellowship Program, University of Texas MD Anderson Cancer Center, Houston, TX. 5. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH. 6. Division of Hematology and Oncology, Department of Medicine, Michigan State University College of Human Medicine, East Lansing, MI. 7. Nancy and James Grosfeld Cancer Genetics Center, Beaumont Cancer Institute, Beaumont Health, Royal Oak, MI. 8. Nancy and James Grosfeld Cancer Genetics Center, Beaumont Cancer Institute, Beaumont Health, Royal Oak, MI; Oakland University William Beaumont School of Medicine, Rochester, MI.
Abstract
INTRODUCTION: The effect of germline BRCA mutations on the outcomes of patients with triple-negative breast cancer (TNBC) is not well understood. MATERIALS AND METHODS: The present retrospective study included women with newly diagnosed TNBC from January 1, 2004 to December 30, 2013. The demographic and tumor characteristics, genetic testing results, and outcomes were collected by a review of the patients' medical records. The outcomes were compared between the BRCA+ and BRCA- women. Kaplan-Meier curves were plotted for survival analysis, and Cox proportional hazard regression was used to determine the predictors of recurrence-free survival. RESULTS: A total of 266 TNBC patients who had undergone BRCA testing were included in the final analysis. Of the 266 patients, 72 (27.0%) tested positive for a pathogenic BRCA mutation and 194 (73.0%) tested negative. BRCA+ women were more likely to be diagnosed with breast cancer at a younger age than were the BRCA- women. Mutation carriers were also more likely to undergo bilateral mastectomy and less likely to receive radiation. The 2- and 5-year overall survival in BRCA+ women was 97.1% and 83.1% and was 97.3% and 89.7% in the BRCA- women, respectively. No statistically significant difference was found in overall survival between the BRCA+ and BRCA- group. No statistically significant difference was noted in the rate of locoregional recurrence, distant recurrence, or recurrence-free survival between the BRCA+ and BRCA- women. CONCLUSION: Our study has demonstrated that BRCA mutation carrier status does not affect overall survival or recurrence-free survival in patients with TNBC.
INTRODUCTION: The effect of germline BRCA mutations on the outcomes of patients with triple-negative breast cancer (TNBC) is not well understood. MATERIALS AND METHODS: The present retrospective study included women with newly diagnosed TNBC from January 1, 2004 to December 30, 2013. The demographic and tumor characteristics, genetic testing results, and outcomes were collected by a review of the patients' medical records. The outcomes were compared between the BRCA+ and BRCA- women. Kaplan-Meier curves were plotted for survival analysis, and Cox proportional hazard regression was used to determine the predictors of recurrence-free survival. RESULTS: A total of 266 TNBC patients who had undergone BRCA testing were included in the final analysis. Of the 266 patients, 72 (27.0%) tested positive for a pathogenic BRCA mutation and 194 (73.0%) tested negative. BRCA+ women were more likely to be diagnosed with breast cancer at a younger age than were the BRCA- women. Mutation carriers were also more likely to undergo bilateral mastectomy and less likely to receive radiation. The 2- and 5-year overall survival in BRCA+ women was 97.1% and 83.1% and was 97.3% and 89.7% in the BRCA- women, respectively. No statistically significant difference was found in overall survival between the BRCA+ and BRCA- group. No statistically significant difference was noted in the rate of locoregional recurrence, distant recurrence, or recurrence-free survival between the BRCA+ and BRCA- women. CONCLUSION: Our study has demonstrated that BRCA mutation carrier status does not affect overall survival or recurrence-free survival in patients with TNBC.
Authors: Cynthia Villarreal-Garza; Ana S Ferrigno; Alejandro Aranda-Gutierrez; Paul H Frankel; Nora H Ruel; Alan Fonseca; Steven Narod; Yanin Chavarri-Guerra; Erika Sifuentes; Maria Cristina Magallanes-Hoyos; Josef Herzog; Danielle Castillo; Rosa M Alvarez-Gomez; Alejandro Mohar-Betancourt; Jeffrey N Weitzel Journal: Cancer Res Commun Date: 2021-12-08
Authors: Katarzyna Pogoda; Anna Niwińska; Elżbieta Sarnowska; Dorota Nowakowska; Agnieszka Jagiełło-Gruszfeld; Janusz Siedlecki; Zbigniew Nowecki Journal: J Oncol Date: 2020-01-27 Impact factor: 4.375
Authors: Allison W Kurian; Paul Abrahamse; Irina Bondarenko; Ann S Hamilton; Dennis Deapen; Scarlett L Gomez; Monica Morrow; Jonathan S Berek; Timothy P Hofer; Steven J Katz; Kevin C Ward Journal: J Natl Cancer Inst Date: 2022-02-07 Impact factor: 11.816
Authors: Yixiao Feng; Mia Spezia; Shifeng Huang; Chengfu Yuan; Zongyue Zeng; Linghuan Zhang; Xiaojuan Ji; Wei Liu; Bo Huang; Wenping Luo; Bo Liu; Yan Lei; Scott Du; Akhila Vuppalapati; Hue H Luu; Rex C Haydon; Tong-Chuan He; Guosheng Ren Journal: Genes Dis Date: 2018-05-12